Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.66 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | PLK4 | O00444 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.43 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2028333 | 0.92 | PDE2A (0.76) | PDE2AMAPTMAPK1NPSR1MEN1 | |
| SCHEMBL2026204 | 0.91 | PDE2A (0.74) | PDE2AMAPTMAPK1NPSR1MEN1 | |
| SCHEMBL2026309 | 0.91 | PDE2A (0.66) | PDE2AMAPTMAPK1NPSR1KMT2A | |
| SCHEMBL12971403 | 0.86 | PDE2A (0.65) | PDE2AMAPTMAPK1NPSR1MEN1 | |
| SCHEMBL2029644 | 0.84 | PDE2A (0.63) | PDE2AMAPTMAPK1NPSR1MEN1 | |
| SCHEMBL2825200 | 0.83 | PDE2A (0.57) | PDE2AMAPTMAPK1KMT2AKDM4E | |
| SCHEMBL2027745 | 0.83 | MAPT (0.62) | MAPTNPSR1SMN1; SMN2LMNATP53 | |
| SCHEMBL2026001 | 0.82 | MAPT (0.55) | PDE2AMAPTNPSR1SMN1; SMN2KDM1A | |
| SCHEMBL12971337 | 0.80 | PDE2A (0.62) | PDE2AMAPTMAPK1NPSR1MEN1 | |
| SCHEMBL2028762 | 0.80 | PDE2A (0.79) | PDE2AMAPTMAPK1NPSR1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1874775-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | claimed |
| US-20110136803-A1 | Triazolophthalazines | NYCOMED GMBH (DE) | 2011-06-09 | — | — | US | claimed |
| US-7671050-B2 | Triazolophthalazines | NYCOMED GMBH (DE) | 2010-03-02 | — | — | US | claimed |
| US-20080280907-A1 | Triazolophthalazines | AALTANA PHARMA AG (DE) | 2008-11-13 | — | — | US | claimed |
| EP-1874775-A2 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | Nycomed GmbH (DE) | 2008-01-09 | — | — | EP | claimed |
| WO-2006072612-A2 | TRIAZOLOPHTHALAZINES AS PDE2- INHIBITORS | NYCOMED GMBH (DE) | 2006-07-13 | — | — | WO | claimed |
| EP-1874775-B1 | TRIAZOLOPHTHALAZINES AS PDE2-INHIBITORS | NYCOMED GMBH (DE) | 2012-10-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080280907-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | PDE2A 1/4885MAPT 3537/4885MAPK1 1338/4885 |
| US-20110136803-A1 | Triazolophthalazines | PDE2A, PDE3A, PDE12 | PDE2A 1/4885MAPT 3537/4885MAPK1 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.